TW202329935A - 用於治療mds相關聯之貧血及其他病況之化合物 - Google Patents

用於治療mds相關聯之貧血及其他病況之化合物 Download PDF

Info

Publication number
TW202329935A
TW202329935A TW111143555A TW111143555A TW202329935A TW 202329935 A TW202329935 A TW 202329935A TW 111143555 A TW111143555 A TW 111143555A TW 111143555 A TW111143555 A TW 111143555A TW 202329935 A TW202329935 A TW 202329935A
Authority
TW
Taiwan
Prior art keywords
weeks
week
subject
compound
pharmaceutically acceptable
Prior art date
Application number
TW111143555A
Other languages
English (en)
Chinese (zh)
Inventor
查里斯 孔
藍尼 丹
Original Assignee
美商阿吉歐斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商阿吉歐斯製藥公司 filed Critical 美商阿吉歐斯製藥公司
Publication of TW202329935A publication Critical patent/TW202329935A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW111143555A 2021-11-16 2022-11-15 用於治療mds相關聯之貧血及其他病況之化合物 TW202329935A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163280069P 2021-11-16 2021-11-16
US63/280,069 2021-11-16
US202263357240P 2022-06-30 2022-06-30
US63/357,240 2022-06-30

Publications (1)

Publication Number Publication Date
TW202329935A true TW202329935A (zh) 2023-08-01

Family

ID=84887868

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111143555A TW202329935A (zh) 2021-11-16 2022-11-15 用於治療mds相關聯之貧血及其他病況之化合物

Country Status (11)

Country Link
US (1) US20250108049A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433057A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543345A (cg-RX-API-DMAC7.html)
KR (1) KR20240107326A (cg-RX-API-DMAC7.html)
AU (1) AU2022390088B2 (cg-RX-API-DMAC7.html)
CA (1) CA3236880A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001431A1 (cg-RX-API-DMAC7.html)
IL (1) IL312679A (cg-RX-API-DMAC7.html)
MX (1) MX2024005852A (cg-RX-API-DMAC7.html)
TW (1) TW202329935A (cg-RX-API-DMAC7.html)
WO (1) WO2023091414A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238659A1 (en) * 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
EP3668513B1 (en) 2017-08-15 2021-11-10 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
JP2022533227A (ja) 2019-05-22 2022-07-21 アジオス ファーマシューティカルズ, インコーポレイテッド N-(4-(4-(シクロプロピルメチル)ピペラジン-1-カルボニル)フェニル)キノリン-8-スルホンアミドの結晶性塩形態

Also Published As

Publication number Publication date
AU2022390088B2 (en) 2026-07-02
WO2023091414A1 (en) 2023-05-25
AU2022390088A1 (en) 2024-05-09
KR20240107326A (ko) 2024-07-09
CA3236880A1 (en) 2023-05-25
MX2024005852A (es) 2024-05-28
CL2024001431A1 (es) 2024-10-25
JP2024543345A (ja) 2024-11-21
US20250108049A1 (en) 2025-04-03
EP4433057A1 (en) 2024-09-25
IL312679A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP6852073B2 (ja) 悪性病変を処置する方法
JP7223998B2 (ja) Axl阻害剤を有効成分として含む固形がん治療剤
AU2011323108B2 (en) Compositions and methods for treating myelofibrosis
TW202529768A (zh) 癌症治療的療法
JP2021181478A (ja) 貧血治療のための組成物及び方法
TW202521120A (zh) 藥物組合物及其應用
JP2021130682A (ja) 悪性腫瘍の治療のための併用療法
JP2021119152A (ja) 悪性腫瘍を処置するため組合せ療法
TWI866427B (zh) 雌激素受體降解劑之給藥方案
US20250108049A1 (en) Compounds for treating mds-associated anemias and other conditions
TW201217361A (en) Method of treating abnormal cell growth
CN103841976A (zh) Akt和mek抑制剂化合物的组合及其使用方法
CA3096156A1 (en) Use of inhibitors of bcr-abl mutants for the treatment of cancer
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
TW202241415A (zh) 通路調節劑、含其的醫藥組成物、其用途和採用其的治療方法
EA050684B1 (ru) Соединения для лечения анемий и других патологических состояний, ассоциированных с mds
CN118382439A (zh) 用于治疗mds相关贫血和其他病症的化合物
TW202308648A (zh) 治療貧血之方法
WO2026076363A1 (en) Compounds for treating mds-associated anemias and other conditions
TWI915832B (zh) 雌激素受體降解劑及cdk4抑制劑之組合
US20250213563A1 (en) Substituted pyrimidin-4(3h)-ones for use in treating cancer
HK40131055A (en) A pharmaceutical combination and use thereof
WO2026008072A1 (zh) 补体因子b抑制剂在制备治疗或预防pnh药物中的用途
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
TW202416992A (zh) 雌激素受體降解劑之給藥方案